Quest Diagnostics

Global News

AiCuris strengthens its management in R&D

Thursday, June 4, 2015 01:20 PM

AiCuris, an anti-infective specialist based in Wuppertal, Germany, has expanded its management staff. Dr. Manickam Rangaraju joined AiCuris as head of development and Dr. Alexander Birkmann has been named head of research. 

More... »

Merck, Dynavax collaborate on immuno-oncology therapies

Thursday, June 4, 2015 01:02 PM

Merck & Co. and Dynavax Technologies have entered into two clinical trial collaboration agreements to investigate the potential synergistic effect of combining immunotherapies from both companies' pipelines: Merck's anti-PD-1 therapy, Keytruda (pembrolizumab), and its investigational anti-interleukin-10 (anti-IL-10) immunomodulator, MK-1966, with Dynavax's investigational toll-like receptor 9 (TLR9) agonist, SD-101.

More... »

Certara endows lectureship in precision dosing at University of Manchester

Thursday, June 4, 2015 08:16 AM

Certara, a global biosimulation technology-enabled drug development consultancy, is endowing a new three-year, full-time position—the Certara lecturer in precision dosing—at the Manchester Pharmacy School, the University of Manchester, England. This lectureship is intended to advance teaching and research into individual dose optimization modeling, and to demonstrate its application to cancer, pediatric and biologic therapies.

More... »

Mylan challenges Teva to submit a formal offer of acquisition

Wednesday, June 3, 2015 12:40 PM

Robert J. Coury, executive chairman of Mylan, has written a letter to Teva Pharmaceutical’s CEO Erez Vigodman, asking for a formal offer or for a cessation of discussions.

More... »

Perrigo to acquire OTC portfolio from GlaxoSmithKline

Wednesday, June 3, 2015 12:39 PM

Perrigo has entered into an agreement to acquire a portfolio of established over-the-counter (OTC) brands from GlaxoSmithKline Consumer Healthcare, in connection with GSK's commitments to the E.C. and other regulators to divest these businesses in the context of the formation of a consumer health joint venture between GSK and Novartis International. Perrigo will acquire the following assets in an all-cash transaction:

More... »

Report: High barriers to entry spur M&A activity in orphan drug sector

Wednesday, June 3, 2015 12:37 PM

High barriers to entry and high pricing levels of drugs that treat orphan diseases will continue to drive acquisition activity in the pharmaceutical sector, according to Moody's Investors Service in the report High Hurdles and High Prices Make Orphan Drugs Appealing M&A Targets.

More... »

Sysmex, LabCorp collaborate on precision medicine in oncology

Wednesday, June 3, 2015 12:30 PM

Sysmex, a Japanese healthcare company, and Laboratory Corporation of America Holdings (LabCorp), a Burlington, N.C.-based healthcare diagnostics company, have formed a collaboration focused on the development of blood-based molecular diagnostic tests to advance precision medicine in oncology. The collaboration combines Sysmex Inostics’ experience in the development of innovative blood-based diagnostic solutions with LabCorp's experience in precision medicine through Covance Drug Development’s involvement in oncology clinical trials and an ability to commercialize clinically-relevant diagnostic tests through LabCorp Diagnostics as such applications are developed.

More... »

Active Biotech adjusts organization, cuts 47 jobs

Wednesday, June 3, 2015 12:29 PM

Active Biotech, a biotechnology company based in Sweden, plans to reduce 47 positions and engage in significant down-sizing of operations due to recent negative trial results.

More... »

Astellas Pharma, Anokion ink R&D deal worth $760M

Wednesday, June 3, 2015 12:27 PM

Astellas Pharma, based in Tokyo, and Anokion, a Switzerland-based biotechnology company, have inked a $760 million agreement to collaborate on type 1 diabetes and celiac disease.

More... »

Juno Therapeutics acquires X-BODY

Wednesday, June 3, 2015 12:25 PM

Juno Therapeutics, a Seattle-based biopharmaceutical company focused on re-engaging the body's immune system to treat cancer, has acquired X-BODY, a privately held biotechnology company with nine employees based in Waltham, Mass. The acquisition furthers Juno's strategy of investing in technologies that augment the company's capabilities to create best-in-class engineered T cells against a broad array of cancer targets. The acquisition brings in-house to Juno an innovative discovery platform that interrogates the human antibody repertoire, rapidly selecting fully human antibodies with desired characteristics, even against difficult targets.

More... »



June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs